Fosmanogepix Therapy of Disseminated Fusarium Infection

Drew J Winston; Patricia A Young; Haran T Schlamm; Gary J Schiller

doi:10.1093/cid/ciad309

Fosmanogepix Therapy of Disseminated Fusarium Infection

Clin Infect Dis. 2023 Sep 18;77(6):848-850. doi: 10.1093/cid/ciad309.

Authors

Drew J Winston¹, Patricia A Young¹, Haran T Schlamm², Gary J Schiller¹

Affiliations

¹ Division of Hematology-Oncology, Department of Medicine, Center for Health Sciences, University of California, Los Angeles, USA.
² HTS Pharma Consulting, San Diego, California, USA.

PMID: 37220752
DOI: 10.1093/cid/ciad309

Abstract

Invasive Fusarium infections cause high mortality. Fosmanogepix, a first-in-class antifungal agent, has potent activity against Fusarium. A patient with acute leukemia with invasive fusariosis, probably involving the central nervous system and caused by Fusarium lactis resistant to currently available antifungal agents, was cured of her infection with fosmanogepix. Fosmanogepix was well tolerated.

Keywords: Fusarium infection; fosmanogepix.

MeSH terms

Antifungal Agents / therapeutic use
Central Nervous System
Female
Fusariosis* / drug therapy
Fusariosis* / microbiology
Humans
Leukemia, Myeloid, Acute* / drug therapy

Substances

Antifungal Agents